Medication classes
Anti-integrin articles covering treatments such as vedolizumab and natalizumab, including safety, effectiveness, approvals, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 3 · 104 articles
People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...
Perianal fistulas are a common, challenging Crohn's complication that often need combined medical and surgical care; understanding local practice patterns helps patients and clinicians anticipate typical treatments and...
Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...
The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...
This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...
The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Adherence to biologic therapy can affect how well treatment controls IBD; understanding whether self-administered subcutaneous vedolizumab has different adherence than IV infusion could influence treatment choices and...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...
This study gives real-world comparative data on two biologic options (vedolizumab vs anti-TNFα) used early in the treatment course for Crohn’s disease, which may help patients and clinicians weigh effectiveness and...
Patients and clinicians choosing among advanced therapies for ulcerative colitis may consider infection-related hospitalization risk as one factor; this study suggests lower risk with ustekinumab versus TNF antagonists...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Vedolizumab, and Anti Integrin. The original article is from Journal of the Canadian Association of...
Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.
For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.
Patients and clinicians choosing a next biologic after prior biologic failure may find evidence here that effectiveness is broadly similar between vedolizumab and ustekinumab overall, with potential differences depending...
Bowel urgency is a common, distressing symptom in ulcerative colitis that matters for quality of life. This analysis indicates vedolizumab may reduce urgency and that early improvement is linked to better clinical and...
People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...
This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...
Patients and clinicians using vedolizumab may be interested because the review links higher trough concentrations to better remission outcomes—most convincingly for endoscopic remission in UC—and provides descriptive...
This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...
Postoperative endoscopic recurrence is common after ileocolonic resection for Crohn’s disease; this study suggests biologic drugs started after surgery are linked to lower recurrence rates. Knowing which biologics...
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
Chronic antibiotic-refractory pouchitis is a common, impactful complication after ileal pouch-anal anastomosis that can worsen quality of life and increase the risk of pouch failure. Patients and clinicians need clearer...
PUC often behaves differently and more aggressively than adult-onset UC; understanding pediatric‑specific causes and treatments could lead to better, more effective therapies for children.
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
People with IBD often need biologic therapy during their reproductive years. This review compiles comparative evidence about pregnancy risks with different biologics to inform decisions about continuing or switching...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
